245 related articles for article (PubMed ID: 27631410)
1. Plasma levels and estimated dopamine D
Ikai S; Suzuki T; Mimura M; Uchida H
Psychopharmacology (Berl); 2016 Dec; 233(23-24):4003-4010. PubMed ID: 27631410
[TBL] [Abstract][Full Text] [Related]
2. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
[TBL] [Abstract][Full Text] [Related]
3. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia.
Uchida H; Mamo DC; Kapur S; Labelle A; Shammi C; Mannaert EJ; Mann SW; Remington G
J Clin Psychiatry; 2008 Aug; 69(8):1281-6. PubMed ID: 18642974
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study.
Mizuno Y; Bies RR; Remington G; Mamo DC; Suzuki T; Pollock BG; Tsuboi T; Watanabe K; Mimura M; Uchida H
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Apr; 37(1):182-7. PubMed ID: 22230651
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
[TBL] [Abstract][Full Text] [Related]
6. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
[TBL] [Abstract][Full Text] [Related]
7. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data.
Takeuchi H; Suzuki T; Bies RR; Remington G; Mamo DC; Pollock BG; Mimura M; Uchida H
Schizophr Res; 2013 Nov; 150(2-3):373-9. PubMed ID: 24028745
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.
Gefvert O; Eriksson B; Persson P; Helldin L; Björner A; Mannaert E; Remmerie B; Eerdekens M; Nyberg S
Int J Neuropsychopharmacol; 2005 Mar; 8(1):27-36. PubMed ID: 15710053
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.
Nakajima S; Uchida H; Bies RR; Caravaggio F; Suzuki T; Plitman E; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Mamo DC; Graff-Guerrero A
Schizophr Bull; 2016 Jan; 42(1):212-9. PubMed ID: 26221049
[TBL] [Abstract][Full Text] [Related]
10. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.
Kimura H; Kanahara N; Sasaki T; Komatsu N; Ishige M; Muneoka K; Ino H; Yoshimura K; Yamanaka H; Suzuki T; Komatsu H; Watanabe H; Shimizu E; Iyo M
J Psychopharmacol; 2016 Aug; 30(8):795-802. PubMed ID: 27371496
[TBL] [Abstract][Full Text] [Related]
11. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial.
Green AI; Brunette MF; Dawson R; Buckley P; Wallace AE; Hafez H; Herz M; Narasimhan M; Noordsy DL; O'Keefe C; Sommi RW; Steinbook RM; Weeks M
J Clin Psychiatry; 2015 Oct; 76(10):1359-65. PubMed ID: 26302441
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.
Uchida H; Kapur S; Mulsant BH; Graff-Guerrero A; Pollock BG; Mamo DC
Am J Geriatr Psychiatry; 2009 Mar; 17(3):255-63. PubMed ID: 19225277
[TBL] [Abstract][Full Text] [Related]
13. Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study.
Takeuchi H; Suzuki T; Bies RR; Remington G; Watanabe K; Mimura M; Uchida H
J Clin Psychiatry; 2014 Nov; 75(11):1209-14. PubMed ID: 25099201
[TBL] [Abstract][Full Text] [Related]
14. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.
Moriguchi S; Bies RR; Remington G; Suzuki T; Mamo DC; Watanabe K; Mimura M; Pollock BG; Uchida H
J Clin Psychopharmacol; 2013 Oct; 33(5):682-5. PubMed ID: 23899638
[TBL] [Abstract][Full Text] [Related]
15. Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.
Yoshida K; Bies RR; Suzuki T; Remington G; Pollock BG; Mizuno Y; Mimura M; Uchida H
Schizophr Res; 2014 Mar; 153(1-3):184-8. PubMed ID: 24491908
[TBL] [Abstract][Full Text] [Related]
16. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
18. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.
Arakawa R; Ito H; Takano A; Takahashi H; Morimoto T; Sassa T; Ohta K; Kato M; Okubo Y; Suhara T
Psychopharmacology (Berl); 2008 Apr; 197(2):229-35. PubMed ID: 18058087
[TBL] [Abstract][Full Text] [Related]
19. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.
Takekita Y; Koshikawa Y; Fabbri C; Sakai S; Sunada N; Onohara A; Nishida K; Yoshimura M; Kato M; Serretti A; Kinoshita T
BMC Psychiatry; 2016 May; 16():172. PubMed ID: 27236412
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.
Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
Clin Pharmacokinet; 2014 Jun; 53(6):533-43. PubMed ID: 24464285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]